MASL Efficiently Targets PDPN, an Early Expressed Biomarker Essential to Contact Normalization

Lead product candidate positioned to prevent tumor growth, invasion and metastasis

MASL Efficiently Targets PDPN, an Early Expressed Biomarker Essential to Contact Normalization

Our lead compound MASL specifically targets podoplanin (PDPN) to disrupt tumor cell communication pathways to inhibit tumor growth and spread, and trigger targeted tumor cell destruction

  • New chemical entity bioactive lectin isolated from maackia amurensus seeds
  • Broad anti-tumor potential validated in preclinical studies conducted with the NCI
  • Animal studies show tumor inhibition with no adverse effects
  • Potential for use as a monotherapy or as neoadjuvant therapy to standard of care
  • Patients can be identified via standard protein and nucleic acid assays for early intervention and potentially prevention